Phoneutria nigriventer spider venom contains 7+ antinociceptive peptide toxins alongside pain-causing components, offering a rich source of non-opioid analgesic leads.
7+ analgesic peptidesin one spider venom, targeting calcium channels, potassium channels, and opioid receptors — diverse non-opioid pain mechanisms
What the researchers found
The pain caused by Phoneutria nigriventer venom is mediated through both peripheral and central mechanisms, involving B2 receptors, serotonin (5-HT4), glutamate (NMDA/AMPA), tachykinin (NK1/NK2), sodium channels (TTX-sensitive), acid-sensing channels (ASIC), and TRPV1 channels.
Despite the venom's pain-causing nature, seven individual toxins (omega-CNTX-Pn4a, omega-CNTX-Pn2a, omega-CNTX-Pn3a, kappa-CNTX-Pn1a, U7-CNTX-Pn1a, delta-CNTX-Pn1a, Gamma-CNTX-Pn1a) and a semi-synthetic peptide (PnPP-19) have shown consistent antinociceptive (pain-relieving) properties in experimental pain models.
The pain-relieving toxins work through mechanisms including calcium channel blockade, potassium channel activation, and modulation of opioid receptors.
Why it matters
The opioid crisis has created urgent demand for non-opioid pain medicines. Spider venom toxins that block pain through novel mechanisms could lead to new analgesics without the addiction risk of opioids.
The fact that multiple pain-relieving peptides exist in a single venom source provides several drug leads to pursue simultaneously.
The numbers in context
7 antinociceptive toxins + PnPP-19; pain via B2/5-HT4/NMDA/AMPA/NK1/NK2/ASIC/TRPV1; analgesia via Ca2+ channels, K+ channels, opioid receptors
How the study worked
This is a review article summarizing published research on the pro-nociceptive and antinociceptive properties of Phoneutria nigriventer venom and its isolated toxins. It covers in vitro mechanism studies and in vivo pain models.
Who was studied
N/A (literature review of venom research)
What this study cannot tell us
This is a review article. The antinociceptive peptides have been tested in animal models but have not entered human clinical trials. Translating venom peptides into safe human medications involves significant challenges including stability, delivery, and side effects.
Some mechanisms described are based on limited studies that need replication.
How to read the evidence
Review-level evidence. Individual toxins have been tested in animal pain models but none have reached human clinical trials.
When this study was published
Published in 2020. Venom-derived analgesic research continues alongside the urgent need for non-opioid pain medications.
The bigger picture
The opioid crisis demands non-opioid pain medications. Spider venom toxins that block pain through novel mechanisms could provide leads for new analgesics without addiction risk. Evolution has optimized these molecules over millions of years.
Questions still open
- Which venom-derived peptide is closest to clinical development?
- Can these analgesic peptides be synthesized economically?
- Do they cause tolerance with repeated use like opioids?
Common questions
How can something that causes pain also relieve it?
Are venom-based drugs realistic?
Read the original research
Pain modulatory properties of Phoneutria nigriventer crude venom and derived peptides: A double-edged sword.
Toxicon : official journal of the International Society on Toxinology, 185, 120-128
Citation
Lauria, Pedro Santana Sales; Villarreal, Cristiane Flora; Casais-E-Silva, Luciana Lyra. (2020). Pain modulatory properties of Phoneutria nigriventer crude venom and derived peptides: A double-edged sword.. Toxicon : official journal of the International Society on Toxinology, 185, 120-128. https://doi.org/10.1016/j.toxicon.2020.07.005